Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme

Br J Haematol. 2019 Feb;184(4):667-671. doi: 10.1111/bjh.15151. Epub 2018 Feb 22.

¹ Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, UK.
² Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
³ Department of Haematology, United Lincolnshire Hospitals NHS Trust, Lincoln, UK.
⁴ Department of Haematology, The Christie Hospital NHS Trust, Manchester, UK.
⁵ Department of Haematology, Milton Keynes Hospital, Milton Keynes, UK.
⁶ Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, UK.
⁷ Department of Clinical Haematology, The Rotherham NHS Foundation Trust, Rotherham, UK.
⁸ NIHR BRC Oxford Molecular Diagnostic Centre, Oxford University Hospitals NHS Trust and Department of Oncology, University of Oxford, John Radcliffe Hospital, Oxford, UK.

No abstract available

Keywords: B-PLL; TP53 deletion, TP53; idelalisib; prolymphocytic leukaemia.

Publication types